Paper20190189
GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death.
Streetly MJ and 5 others. Blood, 2010. Cited by 102 papers, by iCite.
Cite this record
ConductScience Library. GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Papers, record 20190189. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20190189
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Apoptosis | Major topic |
| Cell Cycle | Major topic |
| Galectin 3 | Major topic |
| Multiple Myeloma | Major topic |
| Polysaccharides | Major topic |
| Proto-Oncogene Proteins c-bcl-2 | Major topic |
| Blotting, Western | |
| Caspases | |
| Cell Proliferation | |
| Coculture Techniques | |
| Enzyme Activation | |
| Humans | |
| Membrane Potential, Mitochondrial | |
| Myeloid Cell Leukemia Sequence 1 Protein | |
| Stromal Cells | |
| Tumor Cells, Cultured |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P01CA081534 | NIH |
Source NIH RePORTER
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11306489 | The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. | Cancer Res | 2001 | https://conductscience.org/library/papers/11306489 | PubMed |
| 2 | 18006844 | Chemosensitization of B-cell lymphomas by methylseleninic acid involves nuclear factor-kappaB inhibition and the rapid generation of other selenium species. | Cancer Res | 2007 | https://conductscience.org/library/papers/18006844 | PubMed |
| 3 | 17047062 | Characterization of the nuclear import pathways of galectin-3. | Cancer Res | 2006 | https://conductscience.org/library/papers/17047062 | PubMed |
| 4 | 7853416 | Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. | J Natl Cancer Inst | 1995 | https://conductscience.org/library/papers/7853416 | PubMed |
| 5 | 7722446 | Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. | J Exp Med | 1995 | https://conductscience.org/library/papers/7722446 | PubMed |
| 6 | 11872748 | NF-kappa B as a therapeutic target in multiple myeloma. | J Biol Chem | 2002 | https://conductscience.org/library/papers/11872748 | PubMed |
| 7 | 9064332 | Mitochondrial permeability transition is a central coordinating event of apoptosis. | J Exp Med | 1996 | https://conductscience.org/library/papers/9064332 | PubMed |
| 8 | 11494147 | The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. | Oncogene | 2001 | https://conductscience.org/library/papers/11494147 | PubMed |
| 9 | 10602002 | IL-6 up-regulates mcl-1 in human myeloma cells through JAK / STAT rather than ras / MAP kinase pathway. | Eur J Immunol | 1999 | https://conductscience.org/library/papers/10602002 | PubMed |
| 10 | 12815276 | Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications. | Apoptosis | 2003 | https://conductscience.org/library/papers/12815276 | PubMed |
| 11 | 7696855 | Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. | Glycoconj J | 1994 | https://conductscience.org/library/papers/7696855 | PubMed |
| 12 | 8692888 | Expression of galectin-3 modulates T-cell growth and apoptosis. | Proc Natl Acad Sci U S A | 1996 | https://conductscience.org/library/papers/8692888 | PubMed |
| 13 | 11568006 | Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. | Blood | 2001 | https://conductscience.org/library/papers/11568006 | PubMed |
| 14 | 11023522 | Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. | Blood | 2000 | https://conductscience.org/library/papers/11023522 | PubMed |
| 15 | 12173037 | Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. | Oncogene | 2002 | https://conductscience.org/library/papers/12173037 | PubMed |
| 16 | 15356648 | PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. | Leukemia | 2004 | https://conductscience.org/library/papers/15356648 | PubMed |
| 17 | 10023775 | Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. | Immunity | 1999 | https://conductscience.org/library/papers/10023775 | PubMed |
| 18 | 11877256 | Myeloid cell factor-1 is a critical survival factor for multiple myeloma. | Blood | 2002 | https://conductscience.org/library/papers/11877256 | PubMed |
| 19 | 15843888 | On the role of galectin-3 in cancer apoptosis. | Apoptosis | 2005 | https://conductscience.org/library/papers/15843888 | PubMed |
| 20 | 11593406 | Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. | Oncogene | 2001 | https://conductscience.org/library/papers/11593406 | PubMed |
Cited by64
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 102 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42363882 | Engineering Coil-Coiled Domains for the Design of Modular Theranostic Agents: Galectin-3 as a Targeting Moiety. | Biomacromolecules | 2026 | https://conductscience.org/library/papers/42363882 | PubMed |
| 42294589 | Developing Galectin-3-Targeted Therapeutics in Diseases: Three Distinct Galectin-3 Segments for Targeting. | Expert Rev Mol Med | 2026 | https://conductscience.org/library/papers/42294589 | PubMed |
| 41557013 | Drug resistance in chronic myeloid leukemia: the involvement of Galectin-1 and Galectin-3. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/41557013 | PubMed |
| 41080533 | Galectins-1, -3 and -9 in leukemia: mechanistic insights and therapeutic translation. | Front Immunol | 2025 | https://conductscience.org/library/papers/41080533 | PubMed |
| 40566589 | Galectin-3 Release in the Bone Marrow Microenvironment Promotes Drug Resistance and Relapse in Acute Myeloid Leukemia. | Life (Basel) | 2025 | https://conductscience.org/library/papers/40566589 | PubMed |
| 39769262 | Galectin Plasmatic Levels Reveal a Cluster Associated with Disease Aggressiveness and Kidney Damage in Multiple Myeloma Patients. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39769262 | PubMed |
| 38946426 | Glycosylation in the tumor immune response: the bitter side of sweetness. | Acta Biochim Biophys Sin (Shanghai) | 2024 | https://conductscience.org/library/papers/38946426 | PubMed |
| 38840921 | The role of galectins in mediating the adhesion of circulating cells to vascular endothelium. | Front Immunol | 2024 | https://conductscience.org/library/papers/38840921 | PubMed |
| 38465210 | Ginseng-derived type I rhamnogalacturonan polysaccharide binds to galectin-8 and antagonizes its function. | J Ginseng Res | 2024 | https://conductscience.org/library/papers/38465210 | PubMed |
| 38455415 | Galectin inhibitors and nanoparticles as a novel therapeutic strategy for glioblastoma multiforme. | Am J Cancer Res | 2024 | https://conductscience.org/library/papers/38455415 | PubMed |
| 37175823 | Development of Galectin-3 Targeting Drugs for Therapeutic Applications in Various Diseases. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37175823 | PubMed |
| 36873388 | Galectin functions in cancer-associated inflammation and thrombosis. | Front Cardiovasc Med | 2023 | https://conductscience.org/library/papers/36873388 | PubMed |
| 36814341 | Galectins and galectin-mediated autophagy regulation: new insights into targeted cancer therapy. | Biomark Res | 2023 | https://conductscience.org/library/papers/36814341 | PubMed |
| 36793021 | Novel fusion protein PK5-RL-Gal-3C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity. | BMC Cancer | 2023 | https://conductscience.org/library/papers/36793021 | PubMed |
| 36759557 | Targeting galectin-driven regulatory circuits in cancer and fibrosis. | Nat Rev Drug Discov | 2023 | https://conductscience.org/library/papers/36759557 | PubMed |
| 36725108 | The pleiotropic role of galectin-3 in melanoma progression: Unraveling the enigma. | Adv Cancer Res | 2023 | https://conductscience.org/library/papers/36725108 | PubMed |
| 36364232 | Pectin: A Bioactive Food Polysaccharide with Cancer Preventive Potential. | Molecules | 2022 | https://conductscience.org/library/papers/36364232 | PubMed |
| 35582273 | The bone marrow microenvironment as a mediator of chemoresistance in acute lymphoblastic leukemia. | Cancer Drug Resist | 2019 | https://conductscience.org/library/papers/35582273 | PubMed |
| 34572756 | Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34572756 | PubMed |
| 34572346 | Galectins in Cancer and the Microenvironment: Functional Roles, Therapeutic Developments, and Perspectives. | Biomedicines | 2021 | https://conductscience.org/library/papers/34572346 | PubMed |
Genes18
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20190189
GET https://conductscience.org/api/papers/v1/20190189/references?page=2